Neurocrine Biosciences, Inc. NBIX
Composite 66/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 45/100 — a slight mark against it.
Balance-sheet strength ranks 83/100 — a strong point in its favour. Growth ranks 75/100 — a strong point in its favour. Quality ranks 71/100 — a moderate point in its favour.
Valuation ranks 45/100 — a slight mark against it.
What the company does Neurocrine Biosciences discovers and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders. Its marketed products include INGREZZA for tardive dyskinesia and chorea, Orilissa for endometriosis, and Oriahnn for uterine fibroids, with a pipeline spanning multiple neuropsychiatric and metabolic indications.
Key financials Revenue grew 42% and EPS surged 2311% year-over-year. Gross, operating, and net margins stand at 64%, 23%, and 22%, respectively. ROE is 23% and ROCE is 23%, with debt/equity at 0.11 and net debt/EBITDA near zero.
Stock health The stock has fallen 10% from its 52-week high and shows 3-month momentum of 27%. Sideravia scores Quality 77, Growth 90, Strength 87, Valuation 47, Momentum 68, and Income 50, indicating strong fundamentals but fair valuation.
Price vs fair value The stock trades at a discount of 107% to our fair-value estimate of 346 and a discount of 21% to the 12-month target of 202. Key drivers of the gap include: - Q2 2026 earnings beat and raised guidance (Zacks, GuruFocus, Motley Fool) - Portfolio expansion and record revenue highlighted on earnings calls (Zacks, Moby) - Analysts note continued upside potential despite recent pullback (analyst count 27)
Looking forward The pipeline includes multiple late-stage programs in CNS and metabolic diseases. Forward P/E of 25x and PEG of 2.8x reflect growth expectations, though valuation remains a headwind versus historical multiples. Execution on upcoming catalysts will be critical.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.